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Abstract 25 
Expression of co-inhibitory receptors, such as CTLA-4 and PD-1, on effector T cells is a 26 
key mechanism for ensuring immune homeostasis. Dysregulated co-inhibitory receptor 27 
expression on CD4+ T cells promotes autoimmunity while sustained overexpression on 28 
CD8+ T cells promotes T cell dysfunction or exhaustion, leading to impaired ability to 29 
clear chronic viral infections and cancer1,2.  Here, we used RNA and protein expression 30 
profiling at single-cell resolution to identify a module of co-inhibitory receptors that 31 
includes not only several known co-inhibitory receptors (PD-1, Tim-3, Lag-3, and 32 
TIGIT), but also a number of novel surface receptors. We functionally validated two 33 
novel co-inhibitory receptors, Activated protein C receptor (Procr) and Podoplanin 34 
(Pdpn). The module of co-inhibitory receptors is co-expressed in both CD4+ and CD8+ T 35 
cells and is part of a larger co-inhibitory gene program that is shared by non-responsive T 36 
cells in multiple physiological contexts and is driven by the immunoregulatory cytokine 37 
IL-27. Computational analysis identified the transcription factors Prdm1 and c-Maf as 38 
cooperative regulators of the co-inhibitory module, which we validated experimentally. 39 
This molecular circuit underlies the co-expression of co-inhibitory receptors in T cells 40 
and identifies novel regulators of T cell function with the potential to regulate 41 
autoimmunity and tumor immunity. 42 
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We used single-cell RNA-seq (scRNA-Seq) to analyze co-inhibitory and co-44 
stimulatory receptor expression in 588 CD8+ and 316 CD4+ tumor-infiltrating 45 
lymphocytes (TILs) from B16F10 melanoma3. We found that PD-1, Tim-3, Lag-3, 46 
CTLA-4, 4-1BB, and TIGIT strongly co-vary in CD8+ TILs. CD4+ TILs showed a similar 47 
pattern with the additional co-expression of ICOS, GITR, and OX40 (Fig. 1a, top). 48 
Single-cell mass cytometry (CyTOF) confirmed the surface co-expression of these 49 
receptors (Fig. 1a, bottom, Supplementary Table Information 1). Expression of PD-1, 50 
Lag-3, Tim-3, and TIGIT was tightly correlated on both CD8+ and CD4+ TILs (Fig. 1a, 51 
bottom). Clustering analysis (t-SNE4, Methods) showed two groups of CD8+ TILs 52 
(clusters 1 and 2) (Fig. 1b, Extended Data Fig. 1a,c) where PD-1, Lag-3, Tim-3, and 53 
TIGIT were mainly expressed in cluster 1 cells (Fig. 1b, Extended Data Fig. 1c) as were 54 
LILRB4 (Extended Data Fig. 1a), and co-stimulatory receptors of the TNF-receptor 55 
family, 4-1BB, OX-40, and GITR. In contrast, ICOS and CD226 were less restricted to 56 
cluster 1 (Extended Data Fig. 1a). We further observed two discrete clusters of CD4+ 57 
TILs (clusters 3 and 4) wherein PD-1, Tim-3, Lag-3, and TIGIT co-expression was 58 
restricted to cluster 3 (Fig. 1b, Extended Data Fig. 1c).  59 
The co-expression of co-inhibitory receptors on CD8+ and CD4+ T cells suggests 60 
a common trigger. One candidate is IL-27, a heterodimeric member of the IL-12 cytokine 61 
family that suppresses autoimmunity5, induces IL-10-secreting Type 1 regulatory (Tr1) 62 
cells6,7, and induces expression of Tim-3 and PD-L1 on CD4+ and CD8+ T cells8,9. 63 
Activation of CD4+ and CD8+ T cells in the presence of IL-27 induced Tim-3 (Havcr2), 64 
Lag-3, and TIGIT at mRNA (Fig. 1c) and protein levels (Extended Data Fig. 2a). 65 
Expression of Tim-3, Lag-3, and TIGIT was reduced in IL-27R-deficient T cells, whereas 66 
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PD-1 (Pdcd1) expression was unaffected by IL-27 in vitro (Fig. 1c, Extended Data Fig. 67 
2a). 68 
 CyTOF analysis showed that loss of IL-27ra resulted in loss of cells in cluster 1 of 69 
CD8+ TILs and cluster 3 of CD4+ TILs (Fig. 1d, p-value= 5x10-23 and 6.8x10-7 for CD8+ 70 
and CD4+ respectively, hypergeometric test, Extended Data Fig. 1b,c,d), indicating a 71 
key role for IL-27 in driving co-inhibitory receptor co-expression in both CD4+ and CD8+ 72 
T cells in vivo. Although PD-1 expression wasn’t dependent on IL-27 in vitro, it was 73 
dependent on IL-27R signaling in vivo. In line with the induction of IL-10 by IL-275-7, we 74 
observed reduced IL-10 in IL27ra KO CD8+ TILs (Extended Data Fig. 2b).  75 
scRNA-seq of CD8+ and CD4+ TILs from WT and IL27ra KO mice (Fig. 1e, 76 
Extended Data Fig. 3a,b; Methods) revealed distinct clusters of CD8+ (cluster 5) and 77 
CD4+ (cluster 4) TILs that highly expressed the co-inhibitory receptors PD-1, Tim-3, 78 
Lag-3, and TIGIT. Expression of these genes was decreased in CD8+ TILs from IL27ra 79 
KO mice, while only Tim-3 and Lag-3 were decreased in CD4+ TILs from IL27ra KO 80 
mice (Fig. 1e). Thus, IL-27 drives a module of co-inhibitory receptors that are strongly 81 
co-expressed in vivo together with IL-10. 82 
 The co-inhibitory receptor module could be part of a larger IL-27-driven 83 
inhibitory gene program. We analyzed the mRNA profiles of CD4+ and CD8+ T cells 84 
stimulated in the presence or absence of IL-27. IL-27 induced similar expression 85 
programs in CD4+ and CD8+ T cells (Extended Data Fig. 4a,b). We identified 1,201 86 
genes with IL-27-dependent expression (Methods). We compared the IL-27-driven gene 87 
program to the gene signatures for four different states of T cell non-responsiveness: 88 
CD8+ T cell exhaustion in both cancer3 and chronic viral infection10 and antigen-89 
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specific11 or non-specific (anti-CD3 antibody12) CD4+ T cell tolerance. We found 90 
significant overlap with all of these signatures (Methods, Extended Data Fig. 4c-f).  91 
 Projection of the IL-27/CD8+ cancer T cell exhaustion overlap signature onto the 92 
single-cell profiles of CD8+ TILs marked a distinct subset of cells (Fig. 2a, panel I).  This 93 
subset scored highly for the overlap signatures between the IL-27-driven gene program 94 
and each of the other three states of T cell non-responsiveness (Fig. 2a, panels II-IV). 95 
The transcriptional program induced in IL27ra KO TILs was active in a complimentary 96 
subset of TILs (Methods, Fig. 2a panel V). The control signature from cells stimulated 97 
with IL-27 in vitro showed bimodal distribution and by itself did not detect the same 98 
population of cells (Fig. 2a panel VI). From these analyses, we identified a co-inhibitory 99 
gene module (272 genes) that is shared across multiple states of T cell non-100 
responsiveness (Supplementary Information Table 2). Within this module, we 101 
identified a set of 57 genes encoding cell surface receptors and cytokines, including Tim-102 
3, Lag-3, TIGIT, and IL10 (Fig. 2b), which we further stratified by their expression in  103 
cancer and chronic viral infections (Fig. 2c). Two surface molecules, Procr (protein C 104 
receptor) and Pdpn (podoplanin) were highly expressed in the setting of cancer (Fig. 2c). 105 
Activation of naïve CD4+ and CD8+ T cells in vitro in the presence of IL-27 induced the 106 
expression of Procr and Pdpn (Extended Data Fig. 5a). In vivo, Procr and Pdpn 107 
exhibited IL-27 dependent co-expression with PD-1 and Tim-3 on CD8+ TILs (Extended 108 
Data Fig. 5b).    109 
Procr+ CD8+ TILs exhibited an exhausted phenotype, producing less TNFα and 110 
IL-2 and more IL-10 than Procr- CD8+ TILs (Extended Data Fig. 5c). Growth of 111 
B16F10 melanoma was inhibited in Procr hypomorph (Procrd/d)13 mice (Fig. 2d), and 112 
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Procrd/d CD8+ TILs mice exhibited enhanced TNFα production, but no difference in IL-2, 113 
IFN-γ, or IL-10 (Fig. 2e). Procrd/d TILs exhibited a decreased frequency of Tim-3hiPD-1hi 114 
CD8+ T cells suggesting that Procr signaling promotes a severely exhausted phenotype in 115 
CD8+ T cells14 (Fig. 2f). Adoptive transfer of CD8+ T cells lacking Procr revealed a T 116 
cell specific role for Procr in constraining tumor growth (Extended Data Fig. 5d). 117 
 Although Pdpn can limit CD4+ T cell survival in inflamed tissues15, its  role in T 118 
cell exhaustion is unknown. We observed a significant delay in B16F10 tumor growth in 119 
mice with Pdpn deficiency in T cells  (Pdpn cKO) (Fig. 2g). Pdpn-deficient CD8+ TILs 120 
exhibited enhanced TNFα production but no significant difference in IL-2, IFN-γ, or IL-121 
10 (Fig. 2h).  The frequency of Tim-3hiPD-1hi CD8+ TILs was decreased, indicating a 122 
reduced accumulation of T cells with a severely exhausted phenotype in Pdpn cKO14 123 
(Fig. 2i).  Consistent with previous data15, Pdpn-deficient PD-1+Tim-3+ CD8+ TILs had 124 
higher expression of IL-7Ra, indicating that Pdpn may limit the survival of CD8+ TILs in 125 
the tumor microenvironment (Extended Data Fig. 5e,f). 126 
We identified the transcription factor (TF) Prdm1 as a candidate regulator of the 127 
co-inhibitory module.  Prdm1 is induced in vitro by IL-27 in CD4+ and CD8+ T cells 128 
(Extended Data Fig. 6a), is enriched in TILs with high expression of the IL-27 co-129 
inhibitory module (Extended Data Fig. 3c-f and 6b,c and Methods), and is 130 
overexpressed in exhausted CD8+ TILs (p-value= 0.0004, t-test, Extended Data Fig. 6d). 131 
Network analysis based on profiling of naïve CD8+ T cells from mice with a T cell 132 
specific deletion of Prdm1 (Prdm1 cKO) stimulated with IL-27, showed that Prdm1 133 
regulates multiple genes in the IL-27 co-inhibitory module (Extended Data Fig. 6e, p-134 
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value= 2.32x10-12; hypergeometric test; Methods). This was further supported by Prdm1 135 
Chip-seq data16 (p-value= 2.9x10-8 respectively, hypergeometric test; Fig. 6e; Methods). 136 
CD8+ TILs from B16F10 tumor-bearing Prdm1 cKO mice expressed lower levels 137 
of Tim-3, PD-1, and Procr (Fig. 3a); however, there was no difference in tumor growth 138 
compared to wild type (WT) controls (Fig. 3b), indicating that the reduction of co-139 
inhibitory receptor expression in Prdm1 cKO mice was insufficient to promote effective 140 
anti-tumor immunity. We therefore examined whether other TFs may regulate the co-141 
inhibitory module and compensate for the absence of Prdm1. We analyzed CD8+ TILs 142 
from Prdm1 cKO mice for the expression of genes from the IL-27-driven gene signature 143 
and the signature for exhausted CD8+ TILs (Methods; Supplementary Information 144 
Table 3). We found that only a few genes were upregulated in Prdm-1 cKO CD8+ T cells, 145 
including one TF, c-Maf (p-value < 0.05) (Fig. 3c). Indeed, c-Maf is induced by IL-27, is 146 
co-expressed with Prdm1 in T cells upon IL-27 stimulation (Extended Data Fig. 6a), 147 
and can regulate IL-10 expression17 and T cell exhaustion18. Additionally, many genes 148 
(226 genes, p-value 5.34x10-5, hypergeometric test) in the co-inhibitory gene module 149 
have a binding motif and a reported binding event for c-Maf within their promoter 150 
regions19. 151 
 CD8+ TILs from c-Maf cKO mice exhibited decreased expression of multiple co-152 
inhibitory receptors (Fig. 3d). Interestingly, Prdm1 and c-Maf each impacted co-153 
inhibitory receptor expression only partially (Fig. 3e). As in the Prdm1 cKO mice, c-Maf 154 
cKO mice did not show any differences in tumor growth relative to controls (Fig. 3f). 155 
Notably, Prdm1 expression in c-Maf cKO TILs was similar to that in WT TILs, 156 
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indicating that Prdm1 might drive expression of the co-inhibitory gene module in the 157 
absence of c-Maf. 158 
We addressed whether Prdm1 and c-Maf could act cooperatively to regulate co-159 
inhibitory receptor expression. We found no evidence for a physical interaction between 160 
Prdm1 and c-Maf (data not shown); therefore we examined whether they shared targets. 161 
We combined the network analysis for Prdm1 (Extended Data Fig. 6e) with c-Maf 162 
ChIP-seq data19 and c-Maf targets (Methods). We observed 121 genes in the co-163 
inhibitory module that are affected (RNAseq) or have a direct binding event (ChIP-Seq) 164 
for both Prdm1 and c-Maf (Fig. 4a), but that are not affected in either individual 165 
knockout. This is consistent, among other possibilities, with compensatory (e.g., “OR”) 166 
regulation20. Examination of ATACseq21,22  and ChIP-seq data for  PD-1, Tim-3, Lag-3 167 
and TIGIT shows that Prdm1 and c-Maf can bind both overlapping and non-overlapping 168 
sites in the loci of these receptors and can synergistically trans-activate Tim-3 expression 169 
(Extended Data Fig. 7).  170 
 Mice  with a T cell specific deletion in both Prdm1 and c-Maf (Prdm1/c-Maf 171 
cDKO)  showed normal development of CD4+ and CD8+ T cells in terms of frequency 172 
and expression of memory/activation markers,  although the frequency of Foxp3+ Treg 173 
was increased (Extended Data Fig. 8a). CD4+ and CD8+ TILs from cDKO mice bearing 174 
B16F10 melanomas exhibited a near absence of PD-1, Tim-3, Lag-3, TIGIT, Pdpn, and 175 
Procr expression (Fig. 4b; Extended Data Fig. 8b). Moreover, cDKO CD8+ TILs 176 
exhibited enhanced IL-2 and TNFα production (Extended Data Fig. 8c). In contrast to 177 
singly deficient mice, cDKO mice showed significant control of B16F10 tumor growth 178 
despite the increased frequency of Treg (Fig. 4c). We addressed whether Prdm1 and c-179 
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Maf play a cell-intrinsic role in CD8+ and CD4+ T cells in controlling tumor growth by 180 
using an adoptive transfer model. Although CD8+ T cells from cDKO were able to inhibit 181 
tumor growth with decreased expression of co-inhibitory molecules, these effects were 182 
stronger when Prdm1 and c-Maf were lacking in both CD4+ and CD8+ T cells (Fig. 4d; 183 
Extended Data Fig. 8d). We examined the roles of Prdm-1 and c-Maf in tumor antigen-184 
specific T cell responses using the MC38-OVA tumor model. We observed a significant 185 
reduction in tumor growth in mice receiving cDKO T cells as compared to mice receiving 186 
WT T cells (Extended Data Fig. 8e). We also observed an increase in Ova-specific T 187 
cells in the tumor draining lymph nodes and in OVA-specific IFN-γ and TNF-188 
α producing CD8+ T cells in both the tumor infiltrate and in the periphery in mice 189 
receiving DKO T cells (Fig. 4e,f; Extended Data Fig. 8f). Lastly, we observed an 190 
increase in CD8+ Ki67+ T cells in the periphery of mice receiving DKO T cells (Fig. 4f). 191 
We tested for non-additive effects between Prdm1 and c-Maf by using a binomial 192 
generalized linear model to compare the effect of single knockouts to the cDKO, and 193 
found that 149 out of 940 differentially expressed genes (adj. p-value<0.05, likelihood 194 
ratio test and FDR correction) between WT and cDKO CD8+ TILs have non-additive (i.e. 195 
synergistic) effects (Extended Data Fig. 9, Methods).   196 
Examination of the transcriptional signatures of cDKO CD8+ TILs showed 197 
significant overlap with those of CD8+ Tim-3-PD-1- TILs (Fig. 4g; p-value = 2.8x10-7 198 
one-sample Kolmogorov-Smirnov test, Extended Data Fig. 10a-c, p-value=0.008), 199 
suggesting that loss of both c-Maf and Prdm1 increases the proportion of non-exhausted 200 
CD8+ effectors that exist normally in tumors. We scored the individual scRNA-seq 201 
profiles of CD8+ TILs for the cDKO 940 gene signature and found that expression of the 202 
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cDKO gene signature and the co-inhibitory gene module signature mark mutually 203 
exclusive populations of TILs (Extended Data Fig. 10e). The cDKO signature showed 204 
significant overlap with PD-1+CXCR5+CD8+ T cells, which may represent precursors for 205 
functional effectors in chronic LCMV infection23 (Extended Data Fig. 10d,e, p-value = 206 
1x10-13 one-sample Kolmogorov-Smirnov test). Furthermore, the IL27ra KO TILs 207 
signature also showed significant overlap with this PD-1+CXCR5+CD8+ T cell signature 208 
(p-value < 2.2x10-16 one-sample Kolmogorov-Smirnov test, Extended Data Fig. 10e; 209 
Fig. 2a). Collectively, our data indicate that loss of c-Maf and Prdm1 preferentially 210 
results in loss of the co-inhibitory gene module expression and acquisition of a more 211 
responsive effector T cell state. 212 
In conclusion, we identified a co-inhibitory gene module, which is expressed in 213 
multiple settings of both CD4+ and CD8+ T cell non-responsiveness, along with its 214 
transcriptional regulators. The discovery of this module provides a basis for the 215 
identification of novel co-inhibitory and co-stimulatory receptors that may play an 216 
important role in T cell regulation.   217 
 218 
Acknowledgements 219 
We thank Mary Collins for insightful discussions, Deneen Kozoriz, Junrong Xia, and 220 
Zoujia Chen for technical advice, Samantha Riesenfeld for computational advice, Nicole 221 
Paul and Josh Keegan for CyTOF, and Leslie Gaffney for artwork. This work was 222 
supported by grants from the National Institutes of Health, the American Cancer Society, 223 
the Melanoma Research Alliance, the Klarman Cell Observatory at the Broad Institute, 224 
and the Howard Hughes Medical Institute. 225 
Nature 2016-08-10731F 
 11
 226 
Author Contributions 227 
N.C., A.M., P.R.B., A.C.A., O.R.R., A.R. and V.K.K. designed the experiment; N.C., 228 
A.M., S.K., J.N., C.B., P.R.B., J.D.B, and A.R. developed analytical tools; N.C., A.M., 229 
T.K., N.A, J.N., N.D.M., M.S.K., C.W., H.Z., T.L., Y.E. and P.R.B. performed 230 
experiments; A.M. and M.S. performed computational analysis. N.C. and A.M. wrote the 231 
original draft of the paper and P.R.B., A.C.A, A.R. and V.K.K. reviewed and edited the 232 
paper; A.C.A., A.R., and V.K.K. supervised the project. 233 
 234 
Conflict of Interest 235 
A.C.A. is a member of the SAB for Potenza Therapeutics and Tizona Therapeutics. 236 
V.K.K. has an ownership interest and is a member of the SAB for Potenza Therapeutics 237 
and Tizona Therapeutics. A.C.A.’s and V.K.K.’s interests were reviewed and managed by 238 
the Brigham and Women’s Hospital and Partners Healthcare in accordance with their 239 
conflict of interest policies. A.R. is an SAB member for Thermo Fisher and Syros 240 
Pharmaceuticals and is a consultant for Driver Group. 241 
  242 
Nature 2016-08-10731F 
 12
References 243 
1 Wherry, E. J. & Kurachi, M. Molecular and cellular insights into T cell 244 
exhaustion. Nature reviews. Immunology 15, 486-499, doi:10.1038/nri3862 245 
(2015). 246 
2 Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: Co-247 
inhibitory Receptors with Specialized Functions in Immune Regulation. 248 
Immunity 44, 989-1004, doi:10.1016/j.immuni.2016.05.001 (2016). 249 
3 Singer, M. et al. A Distinct Gene Module for Dysfunction Uncoupled from 250 
Activation in Tumor-Infiltrating T Cells. Cell 166, 1500-1511 e1509, 251 
doi:10.1016/j.cell.2016.08.052 (2016). 252 
4 Maaten L, H. G. Visualizing Data using t-SNE. Journal of Machine Learning 253 
Research, 2579-2605 (2008). 254 
5 Fitzgerald, D. C. et al. Suppression of autoimmune inflammation of the central 255 
nervous system by interleukin 10 secreted by interleukin 27-stimulated T 256 
cells. Nature immunology 8, 1372-1379, doi:10.1038/ni1540 (2007). 257 
6 Awasthi, A. et al. A dominant function for interleukin 27 in generating 258 
interleukin 10-producing anti-inflammatory T cells. Nature immunology 8, 259 
1380-1389, doi:10.1038/ni1541 (2007). 260 
7 Stumhofer, J. S. et al. Interleukins 27 and 6 induce STAT3-mediated T cell 261 
production of interleukin 10. Nature immunology 8, 1363-1371, 262 
doi:10.1038/ni1537 (2007). 263 
8 Zhu, C. et al. An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 264 
expression and T-cell dysfunction. Nature communications 6, 6072, 265 
doi:10.1038/ncomms7072 (2015). 266 
9 Hirahara, K. et al. Interleukin-27 priming of T cells controls IL-17 production 267 
in trans via induction of the ligand PD-L1. Immunity 36, 1017-1030, 268 
doi:10.1016/j.immuni.2012.03.024 (2012). 269 
10 Doering, T. A. et al. Network analysis reveals centrally connected genes and 270 
pathways involved in CD8+ T cell exhaustion versus memory. Immunity 37, 271 
1130-1144, doi:10.1016/j.immuni.2012.08.021 (2012). 272 
11 Burton, B. R. et al. Sequential transcriptional changes dictate safe and 273 
effective antigen-specific immunotherapy. Nature communications 5, 4741, 274 
doi:10.1038/ncomms5741 (2014). 275 
12 Mayo, L. et al. IL-10-dependent Tr1 cells attenuate astrocyte activation and 276 
ameliorate chronic central nervous system inflammation. Brain, 277 
doi:10.1093/brain/aww113 (2016). 278 
13 Castellino, F. J. et al. Mice with a severe deficiency of the endothelial protein C 279 
receptor gene develop, survive, and reproduce normally, and do not present 280 
with enhanced arterial thrombosis after challenge. Thrombosis and 281 
haemostasis 88, 462-472, doi:10.1267/THRO88030462 (2002). 282 
14 Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell 283 
exhaustion and restore anti-tumor immunity. The Journal of experimental 284 
medicine 207, 2187-2194, doi:10.1084/jem.20100643 (2010). 285 
Nature 2016-08-10731F 
 13
15 Peters, A. et al. Podoplanin negatively regulates CD4+ effector T cell 286 
responses. The Journal of clinical investigation 125, 129-140, 287 
doi:10.1172/JCI74685 (2015). 288 
16 Mackay, L. K. et al. Hobit and Blimp1 instruct a universal transcriptional 289 
program of tissue residency in lymphocytes. Science 352, 459-463, 290 
doi:10.1126/science.aad2035 (2016). 291 
17 Apetoh, L. et al. The aryl hydrocarbon receptor interacts with c-Maf to 292 
promote the differentiation of type 1 regulatory T cells induced by IL-27. 293 
Nature immunology 11, 854-861, doi:10.1038/ni.1912 (2010). 294 
18 Giordano, M. et al. Molecular profiling of CD8 T cells in autochthonous 295 
melanoma identifies Maf as driver of exhaustion. EMBO J 34, 2042-2058, 296 
doi:10.15252/embj.201490786 (2015). 297 
19 Ciofani, M. et al. A validated regulatory network for Th17 cell specification. 298 
Cell 151, 289-303, doi:10.1016/j.cell.2012.09.016 (2012). 299 
20 Capaldi, A. P. et al. Structure and function of a transcriptional network 300 
activated by the MAPK Hog1. Nat Genet 40, 1300-1306, doi:10.1038/ng.235 301 
(2008). 302 
21 Karwacz, K. et al. Critical role of IRF1 and BATF in forming chromatin 303 
landscape during type 1 regulatory cell differentiation. Nature immunology 304 
18, 412-421, doi:10.1038/ni.3683 (2017). 305 
22 Sen, D. R. et al. The epigenetic landscape of T cell exhaustion. Science 354, 306 
1165-1169, doi:10.1126/science.aae0491 (2016). 307 
23 Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after 308 
PD-1 therapy. Nature 537, 417-421, doi:10.1038/nature19330 (2016). 309 
24 Chen, L. & Flies, D. B. Molecular mechanisms of T cell co-stimulation and co-310 
inhibition. Nature reviews Immunology 13, 227-242, doi:10.1038/nri3405 311 
(2013). 312 
  313 
Nature 2016-08-10731F 
 14
Figure Legends 314 
Figure 1. Multiple co-inhibitory receptors are expressed as a module on CD4+ and 315 
CD8+ T cells 316 
a) CD4+ and CD8+ tumor-infiltrating lymphocytes (TILs) were harvested from WT mice 317 
bearing B16F10 melanoma tumors. Top panels, co-expression analysis of co-inhibitory 318 
and co-stimulatory receptor mRNA expression as determined by single-cell RNA-seq for 319 
316 CD4+ and 588 CD8+ TILs. Bottom panels, protein expression by CyTOF for 23,656 320 
CD4+ and 36,486 CD8+ TILs. Spearman correlation, followed by dendrogram ordering of 321 
the matrix using Euclidian distance is shown. Data are from biologically independent 322 
experiments. b) TILs from WT mice bearing B16F10 melanoma were analyzed using 323 
CyTOF with a custom panel of antibodies against co-inhibitory and co-stimulatory cell 324 
surface receptors2,24   (Supplementary Information Table 1). Data were analyzed using 325 
vi-SNE. Polygons indicating clusters 1, 2 (in CD8+ T cells), 3 and 4 (in CD4+ T cells) are 326 
shown. Individual panels show expression of the indicated markers. c) Naïve T cells from 327 
either wild type (WT) or IL-27ra deficient (IL27ra KO) mice were stimulated with anti-328 
CD3/CD28 in the presence or absence of IL-27. Indicated co-inhibitory receptors 329 
expression was examined by real-time PCR (qPCR) at 96hr (CD4) and 72hr (CD8). Data 330 
are from biologically independent animals. mean + s.e.m is shown. d) vi-SNE plot 331 
showing WT (red) and IL27ra KO (blue) cells. e) ScRNA-seq of TILs from mice bearing 332 
B16F10 melanoma. Data were analyzed using t-SNE. Polygons indicating cluster 4 (in 333 
CD4+ T cells, orange) and cluster 5 (in CD8+ T cells, blue) are shown. Individual panels 334 
show expression of the indicated markers. Bar graphs show the mean signal intensity for 335 
indicated co-inhibitory receptors from WT (CD4+ (n=849); CD8+ (n=1752)) and IL27ra 336 
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KO (CD4+ (n=628); CD8+ (n=541)) TILs for CyTOF (d) or WT (CD4+ (n=707); CD8+ 337 
(n=825)) and IL27ra KO (CD4+ (n=376); CD8+ (n=394)) TILs for ScRNA-seq (e). Error 338 
bars indicate s.e.m. and *p < 0.05, **p < 0.01, ***p < 0.001; two-sided t-test. 339 
 340 
Figure 2. The IL-27-induced gene program overlaps with multiple signatures of T 341 
cell dysfunction and tolerance 342 
a) Panels I-VI, tSNE plots of the 588 CD8+ single-cell TILs (dots) harvested from WT 343 
mice bearing B16F10 melanoma. Cells are colored in each panel by their signature score 344 
that reflects the relative average expression of the genes in the overlap of the IL-27-345 
induced gene program with the signatures for each of the indicated states of T cell non-346 
responsiveness. Panel VI is a projection of a signature of the differentially expressed 347 
genes between CD8+ TILs from WT and IL27ra KO mice bearing B16 melanoma 348 
(Methods). The contour marks the region of highly scored cells based on cells with 349 
signature scores above the mean. b) Graphical representation of the overlap of 57 IL-27-350 
induced cell surface receptors or cytokine genes with genes expressed in different states 351 
of T cell non-responsiveness. The width of the gray bars reflects the extent of overlap 352 
across states. Significance of the overlap genes between the IL-27 induced and each 353 
state of T cell non-responsiveness state were calculated using Wilcox GST and 354 
camera. c) Graphical representation of the selected overlap genes between the cancer 355 
exhaustion and the chronic viral exhaustion signatures. The shaded background reflects 356 
the ranking based on the extent of overlap with the T cell states depicted. d) WT (n=8) 357 
mice and Procrd/d (n=7) or g) WT (n=5) and Pdpn cKO (n=5) mice were implanted with 358 
B16F10 melanoma. Data are from 3 biologically independent experiments. Mean tumor 359 
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size + s.e.m is shown. ****P<0.0001, repeated measures ANOVA, Sidak’s multiple 360 
comparisons test. e and h) Summary of flow cytometry data for cytokine production in 361 
the indicated CD8+ TILs. f and i) Left panels, representative flow cytometry data  for 362 
Tim-3 and PD-1 expression on the indicated CD8+ TILs. Right panels, summary data. e-i) 363 
*p < 0.05; **p < 0.01; ***p < 0.001, two-sided t-test.   364 
 365 
Figure 3. Prdm1 and c-Maf individually regulate co-inhibitory receptors on T cells 366 
a) Summary data of co-inhibitory receptor expression on CD8+ TILs from WT and 367 
Prdm1 cKO mice bearing B16F10 melanoma. Data are from biologically independent 368 
animals. mean + s.e.m is shown. *p<0.05, ***p<0.001, two-sided t-test. b) WT (n=5) and 369 
Prdm1 cKO (n=5) mice were implanted with B16F10 melanoma. Mean tumor size + 370 
s.e.m. is shown. Data are from 3 biologically independent experiments. c) Left panel, 371 
gene expression in CD8+ TILs from WT and Prdm1 cKO mice bearing B16F10 372 
melanoma was analyzed by n-counter code-set (Supplementary Information Table 3). 373 
Differentially expressed genes are shown as a heatmap. Right panel, expression of c-Maf 374 
in CD8+ TILs from WT and Prdm1 cKO mice as determined by qPCR. Data are from 375 
biologically independent animals. mean + s.e.m is shown. p = 0.03, two-sided t-test. d) 376 
Summary data of co-inhibitory receptor expression on CD8+ TILs from WT and c-Maf 377 
cKO. Data are from biologically independent animals. mean + s.e.m is shown. *p < 0.05, 378 
two-sided t-test. e) Frequency of co-inhibitory receptor expression of Prdm1 cKO (gray 379 
bar) and c-Maf cKO (open bar) CD8+ TILs relative to WT (filled bar). Data are from 3a 380 
and 3d, mean + s.e.m is shown. f) Left panel, WT (n=8) and c-Maf cKO (n=5) mice were 381 
implanted with B16F10 melanoma. Mean tumor size + s.e.m is shown. Data are from two 382 
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biologically independent experiments. Right panel, expression of Prdm1 in CD8+ TILs 383 
from WT and c-Maf cKO mice as determined by qPCR. 384 
 385 
Figure 4. Prdm1 and c-Maf together regulate a co-inhibitory gene module that 386 
determines anti-tumor immunity 387 
a) Network model based on coupling RNAseq gene expression data of naïve CD8+ T 388 
cells from Prdm1 cKO or c-Maf cKO mice stimulated in the presence of IL-27 and 389 
Prdm1 and c-Maf ChIPseq data. Up-regulated genes (green arrows), down-regulated 390 
genes (red arrows), and c-Maf or Prdm1 binding events (gray arrows) are shown. b) 391 
Summary data of indicated co-inhibitory receptors expression on CD8+ TILs from WT 392 
and Prdm1/c-Maf cDKO bearing B16F10 melanoma. Data are from biologically 393 
independent animals. mean + s.e.m is shown. **p < 0.01; ***p < 0.001, two-sided t-test. 394 
c) WT (n=15) and cDKO (n=8) mice were implanted with B16F10 melanoma. Data 395 
shown are from 3 biologically independent experiments. d) CD4+ or CD8+ T cells sorted 396 
from cDKO mice or littermate controls were transferred into Rag1 KO mice at a 2:1 397 
CD4:CD8 ratio followed by subcutaneous injection of B16-OVA (n=5, each condition). 398 
Data are representative of 3 biologically independent experiments. c-d) Mean tumor size 399 
+ s.e.m is shown. *P<0.05, **P<0.01, ****P<0.0001, repeated measures ANOVA, 400 
Sidak’s multiple comparisons test. e-f) T cells were harvested from Rag1 KO mice that 401 
received an adoptive transfer of CD4+ and CD8+ T cells from WT or cDKO mice (2:1 402 
CD4:CD8 ratio) followed by subcutaneous injection of MC38-OVA (Extended Data 403 
Fig. 8e). e) The frequency of IFN-γ and TNF- α CD8+ TILs after OVA-peptide 404 
stimulation, f) the frequency and expression of Ki67+ cells on splenocytes (upper panel), 405 
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and the frequency of IFN-γ and TNF-α CD8+ splenocytes (lower panel) after OVA-406 
peptide stimulation. mean + s.e.m is shown. Data are from biologically independent 407 
animals. *P<0.05, **P<0.01, two-sided t-test. g) 940 differentially expressed genes 408 
between CD8+ TILs from WT and cDKO bearing B16F10 melanoma. (adj. P. value<0.05, 409 
likelihood ratio test and FDR correction) (top panel) and their corresponding expression 410 
pattern in PD-1+Tim-3+ CD8+, PD-1+Tim-3- CD8+, and PD-1-Tim-3- CD8+ TILs.  411 
 412 
  413 
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Methods 414 
Mice 415 
C57BL/6 wild-type (WT), IL27ra KO, and Prdm1 fl/fl mice were obtained from the 416 
Jackson Laboratory (Bar Harbor, ME). c-Maf fl/fl, Pdpn fl/fl mice and Procr delta/delta 417 
mice were previously described13,15,26. Pdpn fl/fl mice were initially obtained from 418 
Christopher Buckley (University of Birmingham, Birmingham, UK) and crossed to 419 
CD4Cre mice to obtain conditional deletion in T cell. CD4Cre mice were purchased from 420 
Taconic (Hudson, NY). Prdm1 fl/fl and c-Maf fl/fl mice were crossed to CD4Cre mice to 421 
generate doubly deficient T cell conditional knockout mice. All experiments were 422 
performed in accordance to the guidelines outlined by the Harvard Medical Area 423 
Standing Committee on Animals (Boston, MA).  424 
 425 
Tumor Experiments 426 
5 × 105 B16F10 melanoma cells (ATCC) were implanted into the right flank of C57BL/6 427 
mice. Tumor size was measured in two dimensions using a caliper. TILs were isolated by 428 
dissociating tumor tissue in the presence of 2.5 mg/ml collagenase D for 20 min before 429 
centrifugation on a discontinuous Percoll gradient (GE Healthcare). Isolated cells were 430 
then used in various assays of T cell function. For antigen specific analysis, we applied 431 
adoptive transfer tumor experiments using T cells from Prdm1/c-Maf cDKO mice, CD4+ 432 
or CD8+ T cells sorted from cDKO mice or littermate controls were transferred into Rag1 433 
KO mice at a 2:1 ratio (CD4: 1 million/mouse and CD8: 0.5 million/mouse) 2 days 434 
before subcutaneous injection of B16-OVA or MC38-OVA tumor. B16-Ova was kind gift 435 
from Kai Wucherpfennig (Dana-Farber Cancer Institute, Boston, MA) and MC38-Ova 436 
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was kind gift from Mark Smyth (QIMR Berghofer, Queensland Institute of Medical 437 
Research, Brisbane Australia). For adoptive transfer tumor experiments using T cells 438 
from Procrd/d mice, CD4+ T cells from WT and CD8+ T cells from WT or Procrd/d mice 439 
were isolated by cell sorting (BD FACS Aria) and transferred into Rag deficient recipient 440 
mice at a 2:1 ratio (WT CD4+: 1 million/mouse and WT or Procrd/d CD8+: 0.5 441 
million/mouse) 2 days before tumor implant. Although we did not blinding or 442 
randomization, at least 5 animals of target gene knock out and control mice were used to 443 
adequately power biological validation experiments throughout the article. All mice used 444 
are C57BL/6 background, both male and female, 6-12 weeks of age, 15-25g. Each 445 
experiment was performed using age, sex matched controls (Supplementary 446 
Information Table 5). 447 
 448 
CyTOF  449 
Antibodies were labeled using MaxPar® Metal Labeling Kits (DVS) by The Longwood 450 
Medical Area CyTOF Antibody Resource and Core. In some experiments, TILs were 451 
enriched using Dynabeads FlowComp Mouse Pan T (CD90.2) Kit (Invitrogen). Cells 452 
were washed and resuspended in CyTOF PBS (PBS + 0.05% sodium azide + 0.5% BSA) 453 
and stained viability marker Rhodium (DVS) following the cocktail of antibodies against 454 
cell-surface molecules for 30 min. Cells were washed again and resuspended in CyTOF 455 
PBS with 4% paraformaldehyde. After 10 min fixation, cells were washed and barcoded 456 
with Cell-ID intercalators (DVS). Before analysis, cells were resuspended in water with 457 
beads and loaded to the CyTOF® Mass Cytometer (DVS). CyTOF data were recorded in 458 
dual-count according to Fluidigm’s recommended settings that calibrated on the fly, 459 
Nature 2016-08-10731F 
 21
combining pulse-count and intensity information. Data obtained as mass peaks for the 460 
channels are processed according to cell event selection criteria. These criteria include 461 
cell viability selection (Pt195), single-cell selection (Intercalator-Ir), and barcoding 462 
selection (Pt194 and Pt198) to identify single-cell events from WT TILs and KO TILs for 463 
further analysis.  464 
 To obtain clusters of cells similar in their protein expression patterns, cells were 465 
clustered using k-means algorithm. Optimal cluster number was estimated using the 466 
within groups sum of squared error (SSE) plot followed by gap statistics with 467 
bootstrapping and first SE max method. These methods suggested 9 clusters as optimal in 468 
the multidimensional space. Applying k-means clustering with (k=9) on our CyTOF data, 469 
resulted in clear distinction between cluster 1 and 2 of the CD8+ TILs and cluster 3 and 4 470 
of the CD4+ TILs. This separation could be further visualized by two-dimensional non-471 
linear embedding of the protein expression profiles using t-stochastic neighborhood 472 
embedding (t-SNE4). The t-SNE plot can then be overlaid by k-means clustering results 473 
to reflect a non-biased approach to the clusters or with intensity of the different markers. 474 
 475 
Flow Cytometry 476 
Single cell suspensions were stained with antibodies against CD4 (RM4-5), CD8 (53-477 
6.7), PD-1 (RMP1-30), Lag-3 (C9B7W), TIGIT (GIGD7), and Tim-3 (5D12), Procr 478 
(eBio1560), and Pdpn (8.1.1.) were obtained from BioLegend (San Diego, CA). Fixable 479 
viability dye eF506 (eBioscience) was used to exclude dead cells. For intra-cytoplasmic 480 
cytokine staining, cells were stimulated with (PMA) (50ng/ml, Sigma-Aldrich, MO), 481 
ionomycin (1µg/ml, Sigma-Aldrich, MO). Permeabilized cells were then stained with 482 
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antibodies against IL-2, TNF-α, IFN-γ or IL-10. All data were collected on a BD LSR II 483 
(BD Biosciences) and analyzed with FlowJo software (Tree Star). 484 
 485 
In vitro T cell differentiation 486 
CD4+ and CD8+ T cells were purified from spleen and lymph nodes using anti-CD4 487 
microbeads and anti-CD8a microbeads (Miltenyi Biotech) then stained in PBS with 0.5% 488 
BSA for 15 min on ice with anti-CD4, anti-CD8, anti-CD62L, and anti-CD44 antibodies 489 
(all from Biolegend, CA). Naïve CD4+ or CD8+ CD62LhighCD44low T cells were sorted 490 
using the BD FACSAria cell sorter. Sorted cells were activated with plate bound anti-491 
CD3 (2μg/ml for CD4 and 1μg/ml for CD8) and anti-CD28 (2μg/ml) in the presence of 492 
rmIL-27 (25ng/ml) (eBioscience). Cells were harvested at various time points for RNA, 493 
intracellular cytokine staining, and flow cytometry. 494 
 495 
Real-time PCR 496 
Total RNA was extracted using RNeasy columns (Qiagen). Reverse transcription of 497 
mRNA was performed in a thermal cycler (Bio-Rad) using iScript™ cDNA Synthesis Kit 498 
(Bio-Rad). Real-time PCR was performed in the Vii7TM Real-Time PCR system (Applied 499 
Biosystems) using the primers for Taqman gene expression (Applied Biosystems). Data 500 
was normalized to the expression of ACTB. 501 
 502 
Nanostring RNA analysis 503 
Expression profiling of TILs. We analyzed gene expression in CD8+ TILs from Prdm1 504 
or c-Maf cKO mice bearing B16F10 melanoma collected on day 14 after tumor 505 
Nature 2016-08-10731F 
 23
implantation, using a custom nanostring code-set of 397 genes representing both the IL-506 
27-driven gene signature (245 genes) and the dysfunctional CD8+ TIL gene signature 507 
(245 genes) (Supplementary Information Table 3). Expression values were normalized 508 
by first adjusting each sample based on its relative value to all samples. This was 509 
followed by subtracting the calculated background (mean.2sd) from each sample with 510 
additional normalization by housekeeping geometric mean, where housekeeping genes 511 
were defined as: Hprt, Gapdh, Actin and Tubb5. Differentially expressed genes were 512 
defined using the function that fits multiple linear models from the Bioconductor package 513 
limma in R27 with p-value<0.05. 514 
 515 
Microarray processing and analysis  516 
Naïve CD4+ and CD8+ T cells were isolated from WT or IL27ra KO mice, and 517 
differentiated in vitro with or without IL-27. Cells were collected at 72 hours for CD8+ 518 
and 96 hours for CD4+ and Affymetrix GeneChip Mouse Genome 430 2.0 Arrays were 519 
used to measure the resulting mRNA levels at these time points. Individual .CEL files 520 
were RMA normalized and merged to an expression matrix using the 521 
ExpressionFileCreator of GenePattern with default parameters28. Gene-specific intensities 522 
were then computed by taking for each gene j and sample i the maximal probe value 523 
observed for that gene. Samples were then transferred to log-space by taking 524 
log2(intensity). 525 
 Differentially expressed genes were annotated as genes with FDR-corrected 526 
ANOVA <0.05 computed between the CD4 with or without IL-27 stimulation (CD4+ 527 
IL27 and Th0) subpopulations (1,202 genes). 468 genes were differentially expressed 528 
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between WT CD8+ T cells stimulated in the presence or absence of IL-27 (p-value<0.05). 529 
234 genes were shared between these two differentially expressed gene lists (p-value = 530 
2.25x10-157, hypergeometric test, background=16,618 (union of genes expressed)). A list 531 
of 972 cell surface/cytokines genes of interest that include: cytokines, adhesion, 532 
aggregation, chemotaxis and other cell surface molecules (Supplementary Information 533 
Table 4) composed using GO annotation in Biomart was used to generate the gene subset 534 
in Fig. 2b and c. 535 
 536 
 537 
RNAseq gene expression profiling of tumor infiltrating cells 538 
Tumor infiltrating CD8+ T cells were isolated from WT, IL27ra KO, Prdm1 cKO, c-Maf 539 
cKO, and Prdm1/c-Maf cDKO tumor bearing mice via FACS sorting on a FACSAria (BD 540 
Biosciences). Tumor infiltrating CD8+ T cells were processed using an adaptation of the 541 
SMART-Seq 2 protocol29, using 5uL of lysate from bulk CD8+ T cells as the input for 542 
each sample during RNA cleanup via SPRI beads (~2,000 cells lysed on average in RLT). 543 
 RNA-seq reads were aligned using Tophat30 (mm9) and RSEM-based 544 
quantification31 using known transcripts (mm9), followed by further processing using the 545 
Bioconductor package DESeq in R32. The data was normalized using TMM 546 
normalization. The TMM method estimates scale factors between samples that can be 547 
incorporated into currently used statistical methods for DE analysis. Post-processing and 548 
statistical analysis was carried out in R31. Differentially expressed genes were defined 549 
using the differential expression pipeline on the raw counts with a single call to the 550 
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function DESeq (adjusted p value<0.1). Heatmap figures were generated using pheatmap 551 
package33. 552 
 553 
Single-cell RNA-seq 554 
CD4+ and CD8+ TILs from WT or IL27ra KO mice bearing B16 melanomas were sorted 555 
into 96-well plates with 5 µl lysis buffer comprised of Buffer TCL (Qiagen) plus 1% 2-556 
mercaptoethanol (Sigma). Plates were then spun down for one minute at 3000rpm and 557 
immediately frozen at -80°C. Cells were thawed and RNA was isolated with 2.2x 558 
RNAClean SPRI beads (Beckman Coulter Genomics) without final elution34. The beads 559 
were then air-dried and processed immediately for cDNA synthesis. Samples were then 560 
processed using the Smart-seq2 protocol35, with minor modifications applied to the 561 
reverse transcription (RT) step (MSK and AR., in preparation). This was followed by 562 
making a 25µl reaction mix for each PCR and performing 21 cycles for cDNA 563 
amplification. Then 0.25 ng cDNA from each cell and ¼ of the standard Illumina 564 
NexteraXT reaction volume were used in both the tagmentation and final PCR 565 
amplification steps. Finally, libraries were pooled and sequenced (50 x 25 paired-end 566 
reads) using a single kit on the NextSeq500 5 instrument. All CD4+ TILs (WT and IL27ra 567 
KO) single-cell RNA-seq data was generated as part of this study. CD8+ TILs single-cell 568 
data includes WT CD8+ TILs data from3 and WT and IL27ra KO CD8+ single-cell data 569 
generated as part of this study. 570 
 571 
Single-cell RNA-seq data preprocessing and expression 572 
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Initial preprocessing was performed as described in3. Briefly, paired reads were mapped 573 
to mouse annotation mm10 using Bowtie36 (allowing a maximum of one mismatch in 574 
seed alignment, and suppressing reads that had more than 10 valid alignments) and TPMs 575 
were computed using RSEM31, and log2(TPM+1) values were used for subsequent 576 
analyses. 577 
 Next, we filtered out low quality cells and cell doublets, maintaining for 578 
subsequent analysis the cells that had (1) 1,000-4,000 detected genes (defined by at least 579 
one mapped read), (2) at least 200,000 reads mapped to the transcriptome, and (3) at least 580 
50% of the reads mapped to the transcriptome, ending with a total of 707 CD4+ and 825 581 
CD8+ WT TILs and 376 CD4+ and 394 CD8+ IL27ra KO TILs. We restricted the genes 582 
considered in subsequent analyses to be the genes expressed at log2(TPM+1)≥2 in at 583 
least twenty percent of the cells. 584 
 After removal of low quality cells the data was normalized using quantile 585 
normalization followed by PCA analysis. PCs 1-10 were chosen for subsequent analysis 586 
due to a drop in the proportion of variance explained following PC10. We used tSNE4 to 587 
visualize single-cells in a two-dimensional non-linear embedding.  588 
 589 
Single-cell RNA-seq clustering and differential expression analysis 590 
For the coupled dataset of WT and IL27ra KO TILs we followed the analysis described in 591 
37. We performed batch correction using ComBat38 and the batch-corrected expression 592 
matrix was then reduced using PCA, PCs 1-13 were chosen for subsequent analysis due 593 
to a drop in the proportion of variance explained following PC13. Next, we cluster the 594 
cells based on their PC scores using the Louvain-Jaccard method using 40 nearest 595 
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neighbors, and the 13 PCs25,39; 11 clusters were detected. We then compared the 596 
composition of each cluster in terms of total number and percentage of WT and IL27ra 597 
KO cells and found cluster 5 to be enriched for WT CD8 TILs cells (p-value= 0.0357, 598 
one sample t-test, Extended Data Fig. 3c,d). Projecting the IL-27 co-inhibitory gene 599 
module onto the single-cell RNA-seq data highlighted clusters 4 and 5 (CD4 and CD8 600 
respectively) (Extended Data Fig. 3e), further showing that in addition to the decrease in 601 
the expression of the co-inhibitory receptors: PD-1, Tim-3, Lag-3 and TIGIT (Fig. 1e), a 602 
significant decrease in the total IL-27 co-inhibitory gene module signature score is 603 
observed with lack of IL-27 signaling (p-value=0.01, t-test, Extended Data Fig. 3f). 604 
Last, we searched for differentially expressed genes between clusters 4/5 and the 605 
rest of the clusters using a nonparametric binomial test37. 606 
 607 
Signature analysis of other states of T cell non-responsiveness 608 
Given that orthogonal approaches were used to generate the various signatures, we first 609 
addressed the robustness of each signature prior to the comparative analysis. First, to 610 
address some of the concerns regarding the definition of these signatures we sub-sampled 611 
the genes in each of the signatures and observed the resulting changes by projection on 612 
the single-cell data. These changes were quantified by randomly selecting decreasing 613 
subsets of genes from each signature (100%, 90% … 30%) and calculating the average 614 
silhouette width of the cells that scored high for the different generated signatures, based 615 
on Euclidian distance between the principal component values used to generate the tSNE 616 
plot.  This analysis shows that the signatures are relatively resilient to this procedure up 617 
to 60% of the original signature (Extended Data Fig. 4e).  618 
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Second, we calculated a signature p-value per cell. The p-value is calculated by 619 
generating random sets of signatures that are composed of genes with a similar average 620 
and variance expression levels as the original signature. This was followed by comparing 621 
the generated scores to the score obtained from the original signature. Cells that had a 622 
statistically significant score (adjusted p-value<0.05) were marked by ‘+’ (Extended 623 
Data Fig. 4f).  624 
For viral exhaustion: Microarray dataset10 was downloaded, followed by RMA. A 625 
signature of viral exhaustion was defined as the genes that are differentially expressed 626 
between chronic and acute viral infection on day 15 and day 30. Genes were ranked 627 
based on a t-test statistic and fold change, each gene rank was then adjusted for multiple 628 
hypotheses testing using false discovery rate (FDR). A threshold of fold change>1.1 and 629 
FDR<0.2 was applied.  630 
For antigen-specific tolerance: Data11 were downloaded. Two groups were 631 
defined, group 1 that includes the PBS and 0.008 μg treated samples (treatment number 632 
1) versus group 2 - 80 μg (treatment number 5 and 6). After Log2 transformation and 633 
quantile normalization, the Limma package was used to estimate the fold changes and 634 
standard errors by fitting a linear model for each gene for the assessment of differential 635 
expression. Genes with p value < 0.05 were selected: 1,845 genes were upregulated of 636 
which 88 were defined as cytokine and cell surface molecules27,40,41. 637 
For antigen non-specific tolerance: Data12 was downloaded. Robust Multi-array 638 
Average (RMA) and quantile normalization were applied for background correction and 639 
normalization using the ExpressionFileCreator module of GenePatterns. Differentially 640 
expressed genes were defined using signal-to-noise ratio (SNR), following FDR 641 
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correction. Differentially expressed genes were identified as genes having a FDR<0.2 642 
between mRNA expression profiles of naïve CD4+ or CD4+ GFP/IL-10+ T cells isolated 643 
from the spleen or cLNs of B6NODF1IL10:GFP mice following nasal treatment with anti-644 
CD3 which attenuates the of progressive phase of EAE. 645 
 For cancer: Data3 was obtained. Briefly, mRNA samples from CD8+Tim-3-PD-1- 646 
(DN) TILs, CD8+Tim-3-PD-1+(SP), and CD8+Tim-3+PD-1+ (DP) TILs were measured 647 
using Affimetrix GeneChip Mouse Genome 430 2.0 Arrays, expression values were RMA 648 
normalized, corrected for batch effects using ComBat38 and gene-specific intensities were 649 
then computed by using the maximal prob intensity per gene, values were transferred to 650 
log-space by taking log2(intensity). Differentially expressed genes were defined as genes 651 
with either an FDR-corrected t-test p-value smaller or equal to 0.2 computed between the 652 
DN and DP subpopulations and a fold-change of at least 1.5 between the two 653 
subpopulations. 654 
The IL-27 co-inhibitory gene module was defined as a union of the overlap 655 
between the IL-27-driven gene program (1,201 genes see Methods: Microarray 656 
processing and analysis) and each of the four different states of T cell non-responsiveness 657 
mentioned above (272 genes, Supplementary Information Table 2).   658 
 For IL27ra KO signature: mRNA samples from FACS sorted CD8+ TILs from 659 
WT and IL27ra KO mice bearing B16 melanomas were measured an adaptation of the 660 
SMART-Seq 2 protocol29 (see Method: RNA expression profiling of tumor infiltrating 661 
cells). Differentially expressed genes were defined as genes with either an FDR-corrected 662 
t-test p-value smaller or equal to 0.2 computed between the WT and IL27ra KO and a 663 
fold-change of at least 1.5 between the two subpopulations. IL27ra KO signature was 664 
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defined as 929 differentially expressed genes in IL27ra KO CD8+ TILs compared to WT 665 
CD8+ TILs. 666 
 667 
Single-cell gene signature computation 668 
As an initial step, the data was scaled (z-score across each gene) to remove bias towards 669 
highly expressed genes. Given a gene signature (list of genes), a cell-specific signature 670 
score was computed by first sorting the normalized scaled gene expression values for 671 
each cell followed by summing up the indices (ranks) of the signature genes. For gene-672 
signatures consisting of an upregulated and downregulated set of genes, two ranking 673 
scores were obtained separately, and the down-regulated associated signature score was 674 
subtracted from the up-regulated generated signature score. A contour plot was added on 675 
top of the tSNE space, which takes into account only those cells that have a signature 676 
score above the mean to further emphasis the region of highly scored cells. 677 
 678 
Network construction 679 
Networks were generated using Cytoscape version 3.2.142. The network model is based 680 
on coupling in vitro RNAseq gene expression data of naïve CD8+ T cells from KO 681 
(Prdm1 or c-Maf) and WT controls stimulated in the presence of IL-27 and previously 682 
published ChIP-seq data for c-Maf and predicted Prdm1 binding sites by motif scan. 683 
More specifically, differentially expressed genes between WT control and KO were 684 
defined using the function that fits multiple linear models from the Bioconductor package 685 
limma in R27 with FDR<0.05. We used published c-Maf ChIP-seq data19 and and Prdm1 686 
ChiP-seq data16. In addition, potential Prdm1 binding sites were detected using FIMO 687 
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(MEME suite - http://meme-suite.org/doc/fimo.html). Association to gene promoters was 688 
based on the following thresholds (upstream=5000, downstream=500 of TSS) and the 689 
overlap with the co-inhibitory module was found to be significant (p-value= 0.009 hyper 690 
geometric, background of 20,000 genes). In the network presentation, we visualize all the 691 
genes that are part of the IL-27 inhibitory module (Extended Data Fig. 6e and Fig. 4a). 692 
 693 
Data availability 694 
Sequence data that support the findings of this study have been deposited in GEO 695 
with the accession codes XXX 696 
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 746 
Extended Data Figure Legends 747 
 748 
Extended Data Figure 1. CyTOF analysis of co-inhibitory and co-stimulatory 749 
receptor co-expression in TILs. a) TILs were harvested from B16F10 melanoma tumor-750 
bearing WT and IL27ra KO mice from Fig. 1b and analyzed using CyTOF (5000 cells 751 
from each). CyTOF data were analyzed using vi-SNE. Applying k-means clustering with 752 
(k=9) on the CyTOF data resulted in clear distinction between clusters 1, 2, 3 and 4. 753 
Polygons indicating clusters 1, 2 (in CD8+ T cells), 3 and 4 (in CD4+ T cells) are shown. 754 
Individual panels show expression of the indicated markers. b) Pie charts show the 755 
distribution of WT or IL27ra KO CD8+ and CD4+ TILs in clusters 1 and 2 (C1 and C2) of 756 
CD8+ TILs and clusters 3 and 4 (C3 and C4) of CD4+ TILs as defined in Fig. 1d. c) 757 
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Independent data of WT and IL27ra KO TILs samples from that shown in Fig. 1 (5000 758 
cells from each). Applying k-means clustering with (k=7) on the CyTOF data resulted in 759 
clear distinction between clusters 1, 2, 3 and 4. Polygons indicating clusters 1, 2 (in CD8+ 760 
T cells), 3 and 4 (in CD4+ T cells) are shown. d) vi-SNE plot highlighting the distribution 761 
of cells from WT (blue) and IL27ra KO (red) in CD8+ TILs clusters 1 and 2 and CD4+ 762 
TILs clusters 3 and 4. Pie charts show the distribution of WT or IL27ra KO CD8+ and 763 
CD4+ TILs in each cluster.  764 
 765 
Extended Data Figure 2. IL-27 induces multiple co-inhibitory receptors on CD4+ 766 
and CD8+ T cells.  767 
a) Naïve T cells from WT or IL27ra KO mice were stimulated in vitro with anti-768 
CD3/CD28 in the presence or absence of IL-27. Expression of co-inhibitory receptors 769 
was determined by flow cytometry. Representative data of 3 biologically independent 770 
experiments are shown. b) Expression of PD-1, Tim-3, Lag-3, TIGIT, and IL-10 on CD8+ 771 
TILs obtained from WT and IL27ra KO mice bearing B16F10 melanoma was determined 772 
by flow cytometry. Thy1.1-IL-10 reporter mice crossed with WT and IL27ra KO mice 773 
were used for IL-10 expression analysis. Representative data of 3 biologically 774 
independent experiments are shown. 775 
 776 
Extended Data Figure 3. Single-cell RNA-seq expression analysis of WT and IL27ra 777 
KO TILs.  778 
a) TILs were harvested from B16F10 melanoma tumor-bearing WT (707 and 825 for 779 
CD4+ and CD8+ respectively) and IL27ra KO (376 and 394 for CD4+ and CD8+ 780 
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respectively) mice as in Fig. 1e. t-SNE plot shows the presence of WT and IL27ra KO 781 
CD4+ and CD8+ TILs as indicated.  b) Clustering using the Louvain-Jaccard method (40 782 
nearest neighbors and 13 principal components25). c) The composition of each cluster in 783 
terms of total number (c) and percentage (d) of WT (red) and IL27ra KO (blue) cells. P-784 
values (*p-value<0.05, **p-value<0.01, ***p-value<0.001) were calculated using one 785 
sample t-test. e) Projection of the IL-27 co-inhibitory module signature on the single-cell 786 
RNA-seq data. The contour plot marks the region of highly expressing cells by taking 787 
into account only those cells that have an expression value above the mean. f) Violin and 788 
box plots displaying the distribution of the IL-27 co-inhibitory module signature score 789 
compared between WT (72 and 98 for CD4+ and CD8+ respectively) and IL27ra KO (85 790 
and 77 for CD4+ and CD8+ respectively) cells in clusters 4 and 5 (CD4+ and CD8+ 791 
respectively, *p-value=0.01, one-sided t-test. The lower and upper hinges in the boxplot 792 
correspond to the first and third quartiles and the horizontal line corresponds to the 793 
median). 794 
 795 
Extended Data Figure 4. Overlap of the IL-27-induced gene program with 796 
signatures from four states of T cell impairment/tolerance/dysfunction. 797 
a) Pearson correlation between WT CD4+ and CD8+ T cells for the 1,201 genes that were 798 
differentially expressed between WT CD4+ T cells stimulated in the presence or absence 799 
of IL-27 (FDR<0.05). b) Expression profile of 118 differentially expressed genes (from 800 
(a)) encoding cell surface receptors and cytokines are shown as a heatmap. c) The IL-27-801 
induced gene program (1,201 genes) was compared to T cell signatures obtained from 802 
four states of T cell non-responsiveness. Number of overlapping genes between the IL-27 803 
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gene program and each signature is depicted. P values (***p < 0.001) were determined 804 
by hypergeometric test: Nasal anti-CD3 – 4.7x10-21, Cancer – 1.2 x10-33, antigen-specific 805 
tolerance – 4 x10-14 and Viral exhaustion – 1.7 x10-26. d) p-value statistics for the 806 
significance of the overlap between the IL-27-induced gene program (1,201) and genes 807 
induced in other states of T cell non-responsiveness using wilcoxGST and camera.  e) 808 
Gene signatures from (c) were sub-sampled and projected onto the CD8+ single-cell TILs 809 
data. Changes were quantified by randomly selecting decreasing subsets of genes from 810 
each signature and calculating the average silhouette width of cells that scored high for 811 
the different generated signatures based on Euclidian distance between the principal 812 
component values used to generate the tSNE plot. The lower and upper hinges in the 813 
boxplot correspond to the first and third quartiles and the horizontal line corresponds to 814 
the median (Methods).   f) Panels I-V, tSNE plots of the 588 CD8+ single-cell TILs (dots) 815 
harvested from WT mice bearing B16F10 melanoma tumor. Cells are colored in each 816 
panel by their signature score. The score reflects the relative average expression of the 817 
genes in the overlap of the IL-27 gene signature with the signatures for each of the 818 
indicated states of T cell non-responsiveness. Panel VI is a projection of a signature of the 819 
differentially expressed genes between CD8+ TILs from WT and IL27ra KO mice bearing 820 
B16 melanomas (Methods). The contour plot marks the region of highly scored cells by 821 
taking into account only those cells that have a signature score above the mean score. 822 
Cells that had a statistically significant score (adjusted p-value<0.05) were marked by ‘+’ 823 
(Methods).   824 
 825 
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Extended Data Figure 5. Characterization of the role of Pdpn and Procr in CD8+ 826 
TILs 827 
a) Pdpn and Procr protein and mRNA expression was determined in T cells from WT and 828 
IL27ra KO stimulated with anti-CD3/CD28 in the presence or absence of IL-27. CD4+ 829 
cells were analyzed at 96hr and CD8+ cells at 72hr. Data are representative flow 830 
cytometry and qPCR data from biologically independent animals. mean + s.e.m is shown. 831 
b) Representative flow cytometry data of 3 independent experiments showing Pdpn and 832 
Procr expression in PD-1+Tim-3+ CD8+ and PD-1-Tim-3- CD8+ TILs obtained from WT 833 
and IL27ra KO mice bearing B16F10 melanoma. c) TILs from WT mice bearing B16F10 834 
melanoma were stimulated with PMA and Ionomycin. Cytokine production in Procr+ or 835 
Procr- CD8+ TILs is shown. Thy1.1-IL-10 reporter mice were used for IL-10 expression 836 
analysis. Data are from biologically independent animals. mean + s.e.m is shown. *p < 837 
0.05; **p < 0.01, paired t-test. d) 5x105 CD8+ T cells from wild type or Procrd/d mice 838 
were transferred along with 1x106 wild type CD4+ T cells to Rag1 KO mice (N=5). On 839 
day 2, 5x105 B16F10 cells were implanted. Mean tumor size + s.e.m is shown. *P<0.05, 840 
repeated measures ANOVA, Sidak’s multiple comparisons test. e) TILs were obtained 841 
from WT and Pdpn cKO mice bearing B16F10 melanoma and stained for the expression 842 
of IL-7Ra. Representative flow cytometry data from 3 independent animals. f) Summary 843 
data of IL-7Ra expression are from biologically independent animals. mean + s.e.m is 844 
shown. *p < 0.05, one-sided t-test.  845 
 846 
Extended Data Figure 6. Prdm1 is a candidate regulator of the co-inhibitory 847 
module.  848 
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a) Log2 fold change RNA levels between naïve CD4+ or CD8+ T cells simulated with or 849 
without IL-27. Data are from two independent experiments. Shown are transcription 850 
factors that are part of the IL-27 co-inhibitory module (Differentially expressed 851 
transcription factors were annotated as genes with FDR-corrected ANOVA <0.05). b) 852 
Transcription factors that are both in the IL-27 co-inhibitory module and are also 853 
overexpressed in clusters 4 and 5 in the single-cell data (clusters that were enriched for 854 
the IL-27 signature, Extended data Fig. 3e,f). Differentially expressed genes between 855 
clusters 4/5 and the rest of the clusters were determined using binomcount.test (binomial 856 
distribution, Methods). Log effect corresponds to log proportion of expressing cells and 857 
p-value is calculated by the probability of finding n or more cells positive for the gene in 858 
clusters 4/5 given the fraction in the rest of the clusters. c) tSNE plot of Fig. 1e. showing 859 
the expression of Prdm1 in WT (707 and 825 for CD4+ and CD8+, respectively) and 860 
IL27ra KO (376 and 394 for CD4+ and CD8+, respectively) cells. d) Normalized RNA 861 
expression levels of Prdm1 in PD-1-Tim-3- (n=3) and PD-1+Tim-3+ (n=3) CD8+ TILs 862 
(mean + s.e. is shown, ***p = 0.0004, two-sided t-test). e) Network model based on 863 
RNAseq gene expression data of naïve CD8+ T cells from Prdm1fl/fl (WT) or 864 
CD4crePrdm1fl/fl (Prdm1 cKO) mice stimulated in the presence of IL-27 and actual 865 
binding events (ChIPseq) data for Prdm119. Green arrows designate genes up-regulated 866 
by Prdm1, red arrows designate genes down-regulated by Prdm1, and dashed gray arrows 867 
mark binding events. 868 
 869 
Extended Data Figure 7. Genomic tracks surrounding the co-inhibitory molecules 870 
Lag3 (a), Pd-1 (b), Tigit (c) and Tim-3 (d) with overlay of Chipseq data of Prdm116 and 871 
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c-Maf19 and ATACseq data of naïve CD4+ cells induced with IL27 for 72h and ATACseq 872 
data of CD8+ T cells 27 days following chronic viral infection22. Regions of binding sites 873 
common to both Prdm1 and c-Maf are indicated by the dotted rectangles. e) Luciferase 874 
activity in 293T cells transfected with pGL4.23 luciferase reporters for depicted 875 
enhancers of Tim-3 together with empty vector (control), constructs encoding Prdm1, c-876 
Maf, or both. Firefly luciferase activity was measured 48h after transfection and is 877 
presented relative to constitutive Renilla luciferase activity. 878 
 879 
Extended Data Figure 8. Immune characterization of Prdm1 cKO, cMaf cKO, and 880 
Prdm1/c-Maf cDKO before and after tumor challenge. 881 
a) Analysis of steady-state immune system in WT, c-Maf cKO, Prdm1 cKO, and 882 
Prdm1/c-Maf cDKO. Summary data for CD4, CD8, Foxp3, CD44, CD62L, and CD69 883 
expression in spleen from WT, c-Maf cKO, Prdm1 cKO andPrdm1/c-Maf cDKO mice. 884 
Data are from biologically independent animals. mean + s.e.m is shown. *p < 0.05; **p 885 
<0.01; ****p < 0.0001, one-way ANOVA and Tukey’s multiple comparisons test. b) co-886 
inhibitory receptor expression in CD4+ TILs from Prdm1/c-Maf cDKO mice. Top panels, 887 
representative flow cytometry data from 3 independent experiments for TILs from WT 888 
and Prdm1/c-Maf cDKO stained for PD-1, Tim-3, TIGIT, Pdpn, and Procr expression. 889 
Bottom panels show summary data. Data are from biologically independent animals. 890 
mean + s.e.m is shown *p < 0.05, two-sided t-test. c) Top panels, representative flow 891 
cytometry data from 3 independent experiments showing cytokine production from CD8+ 892 
TILs from WT and cDKO bearing B16F10 melanoma. Bottom panels, summary data. 893 
Data are from biologically independent animals. mean + s.e.m is shown. *p < 0.05, two-894 
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sided t-test. d) Co-inhibitory receptor expression on CD8+ TILs sorted from B16-OVA-895 
bearing Rag1 KO mice that were transferred with Prdm1/c-Maf cDKO (n=4) or wild type 896 
(n=4) CD4+ and CD8+ T cells as indicated.  Data are from biologically independent 897 
animals. mean + s.e.m is shown. *P<0.05, one-way ANOVA and Tukey’s multiple 898 
comparisons test. e) Rag1 KO mice were transferred with either wildtype or cDKO CD4+ 899 
and CD8+ (2:1 CD4:CD8 ratio) followed by subcutaneous injection of MC38-OVA. Mean 900 
tumor size + s.e.m is shown. ****P<0.0001, repeated measures ANOVA, Sidak’s 901 
multiple comparisons test. On Day 14 post tumor implantation mice were sacrificed and 902 
TILs, spleen and draining Lymph nodes were harvested. f) The frequency of antigen 903 
specific CD8+ T cells in the dLN of mice in (e). 904 
 905 
Extended Data Figure 9. Examination of additive and non-additive (synergistic) 906 
effects of Prdm1 and c-Maf.  907 
a) A Heatmap showing all 940 DE genes between WT (n=5) and cDKO (Prdm1/c-Maf, 908 
n=4) and their expression in single KO (Prdm1 control n=7, Prdm1 KO n=3, cMaf 909 
control n=4 and cMaf KO n=3) mice. The red markings on the top of the heatmap 910 
indicate genes on whose expression the two knockouts have a statistically significant (p-911 
value<0.05) non-additive effect in the cDKO (149 out of 940 DE genes). b) Volcano plot 912 
of the same analysis as in (a) for global gene expression. Genes whose expression in the 913 
two single knockouts have a statistically significant (p-value<0.05) non-additive effect in 914 
the cDKO (1144 out of 12,906 genes) and had abs (coefficient)>1 (779 out of 1144) are 915 
shown in orange. 916 
 917 
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Extended Data Figure 10. Comparison of gene expression between Prdm1/c-Maf 918 
cDKO TILs and CD8+ TILs populations from wild type mice. a) Barcode enrichment 919 
plot displaying two gene sets in a ranked gene list. The ranked gene list was defined as 920 
fold change in gene expression between Prdm1/c-Maf cDKO and WT CD8+ TILs. The 921 
three gene sets consist of differentially expressed genes between: PD-1+Tim-3+ CD8+ 922 
(DP, n=3) and PD-1-Tim-3- CD8+ (DN, n=3) TILs, PD-1+Tim-3+ CD8+ (DP) TILs and 923 
Memory CD8+ (n=3), and PD-1+Tim-3- CD8+ (SP, n=3) and PD-1-Tim-3- CD8+ (DN) 924 
TILs. b) This analysis was followed by four statistical tests (one-sample Kolmogorov-925 
Smirnov test, mean-rank gene set test (wilcoxGST), hypergeometric, and competitive 926 
gene set test accounting for inter-gene correlation) for enrichment of these signatures in 927 
the cDKO expression profile. c) WT versus cDKO volcano plot. Green indicates genes 928 
that were up-regulated in the PD-1-Tim-3- CD8+ (DN) TILs and red indicates genes that 929 
were up-regulated in the PD-1+Tim-3+ CD8+ (DP) TILs. d) WT versus cDKO volcano 930 
plot. Red indicates genes that were up-regulated in PD-1+CXCR5+CD8+ T cells and green 931 
indicates genes that were up-regulated in PD-1+CXCR5-CD8+ T cells in chronic LCMV 932 
infection23. e). A tSNE plot of the 588 CD8+ TILs harvested from WT mice bearing 933 
B16F10 melanoma tumors, colored by the relative signature score for the co-inhibitory 934 
module (272 genes, Supplementary Information Table 2), the cDKO signature (shown 935 
in (g)), and the PD-1+CXCR5+CD8+ T cell signature from chronic virus infection23. The 936 
contour plot marks the region of highly scored cells by taking into account only those 937 
cells that have a signature score above the mean. 938 
 939 
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